Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund.
Thanx for your patience as we catch-up.

Tokai Pharmaceuticals (Cambridge, MA) a clinical-stage pharmaceutical company focused on prostate cancer, closed a $23M Series D financing. Participants include Novartis Venture Fund and Apple Tree Partners.

Akebia Therapeutics (Cincinnati, OH) a clinical-stage pharmaceutical focused on anemia and vascular disorders, closed a $22M Series B financing. Participants include Novartis Venture Fund, Venture Investors, Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners, Sigvion Capital and AgeChem.

Symetis (Switzerland) a clinical-stage medical device company focused on a transcatheter aortic valve implantation, closed a $25.8M Series C financing. Participants include Endeavour Vision, NBGI Ventures, Truffle Capital, Novartis Venture Fund, Wellington Partners Venture Capital, Vinci Capital, Renaissance PME, Banexi Venture Partners and BiomedInvest.

Covagen (Switzerland) a development-stage biopharmaceutical company focused on a protein scaffold platform (Fynomer) for therapeutic use, closed a $6.5M Series A financing. Participants include Seroba Kernel Life Sciences, Edmond de Rothschild Investment Partners, MP Healthcare Venture Management, Novartis Venture Fund and Ventech.

Euthymics Bioscience (Cambridge, MA) a clinical-stage small molecule company focused on CNS disorders and depression, closed a $24M Series A financing. Participants include Novartis Venture Fund, Venture Investors, H&Q Capital Management and GBS Venture Partners.

Cylene Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on multiple myeloma, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments.

Cylene Pharmaceuticals (Sa Diego, CA) a clinical-stage small molecule company focused on broad spectrum anti-proliferative activity against diverse cancer set of cancers, closed a $12M Series D financing. Participants include Sanderling Ventures, HBM BioVentures, Novartis Venture Fund, BioVentures Investors, Lilly Ventures and Morningside Venture Investments.

Okairos (Switzerland) a clinical-stage biopharmaceutical company developing T-cell vaccines against infectious diseases such as malaria, HIV, hepatitis C and influenza, closed a $20.8M Series B financing. Participants include Versant Ventures, Boehringer Ingelheim Venture Fund, BioMedPartners, Life Science Partners and Novartis Venture Fund.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.